These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Assessment and management of treatment-refractory obsessive-compulsive disorder in children. Bloch MH; Storch EA J Am Acad Child Adolesc Psychiatry; 2015 Apr; 54(4):251-62. PubMed ID: 25791142 [TBL] [Abstract][Full Text] [Related]
32. The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity. Brakoulias V Expert Opin Pharmacother; 2014 Jul; 15(10):1321-3. PubMed ID: 24866422 [TBL] [Abstract][Full Text] [Related]
34. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469 [TBL] [Abstract][Full Text] [Related]
35. An update on the pharmacological treatment of obsessive-compulsive disorder. Fontenelle LF; Nascimento AL; Mendlowicz MV; Shavitt RG; Versiani M Expert Opin Pharmacother; 2007 Apr; 8(5):563-83. PubMed ID: 17376013 [TBL] [Abstract][Full Text] [Related]
36. Pharmacotherapy in children and adolescents with obsessive-compulsive disorder. Grados M; Scahill L; Riddle MA Child Adolesc Psychiatr Clin N Am; 1999 Jul; 8(3):617-34, x. PubMed ID: 10442233 [TBL] [Abstract][Full Text] [Related]
38. Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD. O'Neill J Evid Based Ment Health; 2014 May; 17(2):58-9. PubMed ID: 24713316 [No Abstract] [Full Text] [Related]
39. Pharmacological management of obsessive-compulsive disorder: a review for clinicians. McDonough M; Kennedy N Harv Rev Psychiatry; 2002; 10(3):127-37. PubMed ID: 12023928 [TBL] [Abstract][Full Text] [Related]
40. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Talaei A; Hosseini FF; Aghili Z; Akhondzadeh S; Asadpour E; Mehramiz NJ; Forouzanfar F Can J Physiol Pharmacol; 2020 Apr; 98(4):236-242. PubMed ID: 32228235 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]